Trial Profile

To evaluate MK-6070 in combination with ifinatamab deruxtecan in certain patients with SCLC

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Aug 2024 New trial record
06 Aug 2024 According to Daiichi Sankyo media release, Daiichi Sankyo and Merck & Co, enter into global development and commercialization agreement for MK-6070, The companies are planning to evaluate MK-6070 in combination with ifinatamab deruxtecan in certain patients with SCLC, as well as other potential combinations. Merck & Co., Inc., Rahway, NJ, USA obtained MK-6070 through its acquisition of Harpoon Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com